Despite winning an alopecia areata approval for its drug Leqselvi in July, Sun Pharma will have to wait a while longer to ...

According to Citi, the delay in the launch of Sun Pharma's alopecia areata drug, Leqselvi, could impact its near-term ...

Incyte filed a lawsuit to try to block the launch of Leqselvi, claiming that the drug infringed a US patent (No. 9,662,335) ...

This decision delays Sun Pharma's planned US launch of the product, which could be deferred for several months if the company ...

In the worst-case scenario, an unfavourable judgment would prevent Sun Pharma from launching Leqselvi until the patent expires, delaying its market entry.

After a US Court blocked the launch of Leqselvi, a drug used to treat severe alopecia areata, shares of Sun Pharma plunged ...

Sun Pharmaceuticals Ltd. announced on Saturday that the US District Court of New Jersey has granted a preliminary injunction ...

Leqselvi, projected to generate around $200 million in sales over the next three to four years for Sun Pharma, was slated for ...

Shares of Sun Pharmaceuticals fell by 3.62% in an early trading session to Rs 1,791.15 on BSE after the firm announced on ...

Given the investments of around $576 million and the peak revenues potential upwards of $200 million, four years down the ...

Shares of Sun Pharmaceutical Industries declined five per cent to Rs 1,766.15 in early trade on the BSE on Monday following a ...